1
|
Xue M, Tan L, Zhang S, Wang JN, Mi X, Si W, Qiao Y, Lao Z, Meng X, Yang Y. Chemoenzymatic synthesis of sialyl-α2,3-lactoside-functionalized BSA conjugate inhibits influenza infection. Eur J Med Chem 2024; 276:116633. [PMID: 38968785 DOI: 10.1016/j.ejmech.2024.116633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Revised: 06/25/2024] [Accepted: 06/25/2024] [Indexed: 07/07/2024]
Abstract
Influenza remains a global public health threat, and the development of new antivirals is crucial to combat emerging drug-resistant influenza strains. In this study, we report the synthesis and evaluation of a sialyl lactosyl (TS)-bovine serum albumin (BSA) conjugate as a potential multivalent inhibitor of the influenza virus. The key trisaccharide component, TS, was efficiently prepared via a chemoenzymatic approach, followed by conjugation to dibenzocyclooctyne-modified BSA via a strain-promoted azide-alkyne cycloaddition reaction. Biophysical and biochemical assays, including surface plasmon resonance, isothermal titration calorimetry, hemagglutination inhibition, and neuraminidase inhibition, demonstrated the strong binding affinity of TS-BSA to the hemagglutinin (HA) and neuraminidase (NA) proteins of the influenza virus as well as intact virion particles. Notably, TS-BSA exhibited potent inhibitory activity against viral entry and release, preventing cytopathic effects in cell culture. This multivalent presentation strategy highlights the potential of glycocluster-based antivirals for combating influenza and other drug-resistant viral strains.
Collapse
Affiliation(s)
- Mingming Xue
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Lintongqing Tan
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Shuai Zhang
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Jia-Ning Wang
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Xue Mi
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Weixue Si
- CanSino Biologics Inc, 185 South Avenue, TEDA West District, Tianjin, 300457, China
| | - Ying Qiao
- CanSino Biologics Inc, 185 South Avenue, TEDA West District, Tianjin, 300457, China
| | - Zhiqi Lao
- Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
| | - Xin Meng
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China.
| | - Yang Yang
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China.
| |
Collapse
|
2
|
Xue M, Deng A, Wang JN, Mi X, Lao Z, Yang Y. A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity. Int J Biol Macromol 2024; 275:133564. [PMID: 38955298 DOI: 10.1016/j.ijbiomac.2024.133564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 06/26/2024] [Accepted: 06/28/2024] [Indexed: 07/04/2024]
Abstract
Influenza viruses contribute significantly to the global health burden, necessitating the development of strategies against transmission as well as effective antiviral treatments. The present study reports a biomimetic strategy inspired by the natural antiviral properties of mucins. A bovine serum albumin (BSA) conjugate decorated with the multivalent neuraminidase inhibitor Zanamivir (ZA-BSA) was synthesized using copper-free click chemistry. This synthetic pseudo-mucin exhibited potent neuraminidase inhibitory activity against several influenza strains. Virus capture and growth inhibition assays demonstrated its effective absorption of virion particles and ability to prevent viral infection in nanomolar concentrations. Investigation of the underlying antiviral mechanism of ZA-BSA revealed a dual mode of action, involving disruption of the initial stages of host-cell binding and fusion by inducing viral aggregation, followed by blocking the release of newly assembled virions by targeting neuraminidase activity. Notably, the conjugate also exhibited potent inhibitory activity against Oseltamivir-resistant neuraminidase variant comparable to the monomeric Zanamivir. These findings highlight the application of multivalent drug presentation on protein scaffold to mimic mucin adsorption of viruses, together with counteracting drug resistance. This innovative approach has potential for the creation of antiviral agents against influenza and other viral infections.
Collapse
Affiliation(s)
- Mingming Xue
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin 300457, China
| | - Ang Deng
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin 300457, China
| | - Jia-Ning Wang
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin 300457, China
| | - Xue Mi
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin 300457, China
| | - Zhiqi Lao
- Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
| | - Yang Yang
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin 300457, China.
| |
Collapse
|
3
|
Aigbogun OP, Phenix CP, Krol ES, Price EW. The Chemistry of Creating Chemically Programmed Antibodies (cPAbs): Site-Specific Bioconjugation of Small Molecules. Mol Pharm 2023; 20:853-874. [PMID: 36696533 DOI: 10.1021/acs.molpharmaceut.2c00821] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Small-molecule drugs have been employed for years as therapeutics in the pharmaceutical industry. However, small-molecule drugs typically have short in vivo half-lives which is one of the largest impediments to the success of many potentially valuable pharmacologically active small molecules. The undesirable pharmacokinetics and pharmacology associated with some small molecules have led to the development of a new class of bioconjugates known as chemically programmed antibodies (cPAbs). cPAbs are bioconjugates in which antibodies are used to augment small molecules with effector functions and prolonged pharmacokinetic profiles, where the pharmacophore of the small molecule is harnessed for target binding and therefore biological targeting. Many different small molecules can be conjugated to large proteins such as full monoclonal antibodies (IgG), fragment crystallizable regions (Fc), or fragment antigen binding regions (Fab). In order to successfully and site-specifically conjugate small molecules to any class of antibodies (IgG, Fc, or Fab), the molecules must be derivatized with a functional group for ease of conjugation without altering the pharmacology of the small molecules. In this Review, we summarize the different synthetic or biological methods that have been employed to produce cPAbs. These unique chemistries have potential to be applied to other fields of antibody modification such as antibody drug conjugates, radioimmunoconjugates, and fluorophore-tagged antibodies.
Collapse
Affiliation(s)
- Omozojie P Aigbogun
- Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, S7N-5C9 Saskatchewan, Canada
| | - Christopher P Phenix
- Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, S7N-5C9 Saskatchewan, Canada
| | - Ed S Krol
- Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, S7N-5E5 Saskatchewan, Canada
| | - Eric W Price
- Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, S7N-5C9 Saskatchewan, Canada
| |
Collapse
|
4
|
Qin HJ, Li S, Zhu YB, Bao YB, Tang Q, Liu WB, Zhong M, Zhao Y, Yang Y. Oseltamivir modified bovine serum albumin inhibits neuraminidase activity and accumulates virion particles to disturb influenza virus replication. Carbohydr Res 2022; 520:108631. [PMID: 35839640 DOI: 10.1016/j.carres.2022.108631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 07/03/2022] [Accepted: 07/05/2022] [Indexed: 11/25/2022]
Abstract
The preparation of oseltamivir-bovine serum albumin conjugate (OS-BSA) for use as a multivalent influenza neuraminidase (NA) inhibitor is reported. Briefly, the oseltamivir azidohexyl ester was synthesized and covalently bound via an orthogonal attachment to bicyclononyne-modified BSA using copper-free click chemistry. Primary antiviral assays on NA protein and cellular levels showed that the synthetic multivalent OS-BSA conjugate was a more effective inhibitor than monomeric OS azidohexyl ester. Further investigation of the antiviral mechanism found that the prepared OS-BSA could not only be used as a multivalent NA inhibitor but also acted as an adsorbent for the aggregation of virion particles, contributing to the inhibition of the influenza viral replication cycle. Our findings provide insight into the antiviral mechanism of multivalent NA inhibitors and form a basis for the development of novel antiviral agents.
Collapse
Affiliation(s)
- Hai-Juan Qin
- Research Centre of Modern Analytical Technology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Shuang Li
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Yu-Bo Zhu
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Yan-Bin Bao
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Qi Tang
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Wen-Bin Liu
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China
| | - Ming Zhong
- Medical College of Shaoguan University, Shaoguan, 512026, Guangdong Province, China.
| | - YueTao Zhao
- School of Life Sciences, Central South University, Changsha, 410013, Hunan Province, China.
| | - Yang Yang
- Research Centre of Modern Analytical Technology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, No. 29, 13th Avenue, TEDA, Tianjin, 300457, China.
| |
Collapse
|
5
|
Wei X, Du W, Duca M, Yu G, de Vries E, de Haan CAM, Pieters RJ. Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors. J Med Chem 2022; 65:7312-7323. [PMID: 35549211 PMCID: PMC9150099 DOI: 10.1021/acs.jmedchem.2c00319] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Divalent inhibitors
of the neuraminidase enzyme (NA) of the Influenza
A virus were synthesized with vastly different spacers. The spacers
varied from 14 to 56 atoms and were relatively rigid by way of the
building blocks and their connection by CuAAC. As the ligand for these
constructs, a Δ4-β-d-glucoronide was
used, which can be prepared form N-acetyl glucosamine.
This ligand showed good NA inhibitory potency but with room for improvement
by multivalency enhancement. The synthesized compounds showed modest
potency enhancement in NA activity assays but a sizeable potency increase
in a 4-day cytopathic effect assay. The demonstration that the compounds
can also inhibit hemagglutinin in addition to NA may be the cause
of the enhancement.
Collapse
Affiliation(s)
- Xuan Wei
- Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, Utrecht NL-3508 TB, The Netherlands
| | - Wenjuan Du
- Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands
| | - Margherita Duca
- Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, Utrecht NL-3508 TB, The Netherlands
| | - Guangyun Yu
- Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, Utrecht NL-3508 TB, The Netherlands
| | - Erik de Vries
- Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands
| | - Cornelis A M de Haan
- Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands
| | - Roland J Pieters
- Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, Utrecht NL-3508 TB, The Netherlands
| |
Collapse
|
6
|
Abstract
The neuraminidase (NA) of influenza A and B viruses plays a distinct role in viral replication and has a highly conserved catalytic site. Numerous sialic (neuraminic) acid analogs that competitively bind to the NA active site and potently inhibit enzyme activity have been synthesized and tested. Four NA inhibitors are now licensed in various parts of the world (zanamivir, oseltamivir, peramivir, and laninamivir) to treat influenza A and B infections. NA changes, naturally occurring or acquired under selective pressure, have been shown to reduce drug binding, thereby affecting the effectiveness of NA inhibitors. Drug resistance and other drawbacks have prompted the search for the next-generation NA-targeting therapeutics. One of the promising approaches is the identification of monoclonal antibodies (mAbs) targeting the conserved NA epitopes. Anti-NA mAbs demonstrate Fab-based antiviral activity supplemented with Fc-mediated immune effector functions. Antiviral Fc-conjugates offer another cutting-edge strategy that is based on a multimodal mechanism of action. These novel antiviral agents are composed of a small-molecule NA inhibitor and an Fc-region that simultaneously engages the immune system. The significant advancements made in recent years further support the value of NA as an attractive target for the antiviral development.
Collapse
Affiliation(s)
- Larisa Gubareva
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30329-4027, USA
| | - Teena Mohan
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30329-4027, USA
| |
Collapse
|
7
|
Lv X, Wang P, Li C, Cheng S, Bi Y, Li X. Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses. J Med Chem 2021; 64:17403-17412. [PMID: 34797984 DOI: 10.1021/acs.jmedchem.1c01531] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Antiviral therapy of influenza virus infections depends heavily on two viral neuraminidase (NA) inhibitors, oseltamivir (OSV) and zanamivir (ZNV). The efficacy of OSV is challenged by the development of viral resistance, while the clinical use of ZNV is limited by its poor pharmacokinetic profile and requirement for twice-daily intranasal administration. We have developed a novel NA inhibitor by conjugating ZNV to cholesterol. The ZNV-cholesterol conjugate showed markedly improved antiviral efficacy and plasma half-life compared with ZNV. Single-dose administration of the conjugate protected the mice from lethal challenges with wild-type or mutant H1N1 influenza viruses bearing an OSV-resistant H275Y-substitution. Mechanistic studies showed that the conjugate targeted the cell membrane and entered the host cells, thereby inhibiting the NA function and the assembly of progeny virions. The ZNV-cholesterol conjugate represents a potential new treatment for influenza infections with sustained effect. Cholesterol conjugation may be an effective strategy for improving the pharmacokinetics and efficacy of other small-molecule therapeutics.
Collapse
Affiliation(s)
- Xun Lv
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Chaoyang District, Beijing 100101, China.,Savaid Medical School, University of Chinese Academy of Sciences, Huairou District, Beijing 101408, China
| | - Pengfei Wang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Chaoyang District, Beijing 100101, China.,Savaid Medical School, University of Chinese Academy of Sciences, Huairou District, Beijing 101408, China
| | - Chenning Li
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Chaoyang District, Beijing 100101, China.,Savaid Medical School, University of Chinese Academy of Sciences, Huairou District, Beijing 101408, China
| | - Shuihong Cheng
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Chaoyang District, Beijing 100101, China.,Savaid Medical School, University of Chinese Academy of Sciences, Huairou District, Beijing 101408, China
| | - Yuhai Bi
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Chaoyang District, Beijing 100101, China.,Savaid Medical School, University of Chinese Academy of Sciences, Huairou District, Beijing 101408, China.,Center for Influenza Research and Early-warning, Chinese Academy of Sciences (CASCIRE), Chaoyang District, Beijing 100101, China
| | - Xuebing Li
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Chaoyang District, Beijing 100101, China.,Savaid Medical School, University of Chinese Academy of Sciences, Huairou District, Beijing 101408, China.,Center for Influenza Research and Early-warning, Chinese Academy of Sciences (CASCIRE), Chaoyang District, Beijing 100101, China
| |
Collapse
|
8
|
Nudelman A. Dimeric Drugs. Curr Med Chem 2021; 29:2751-2845. [PMID: 34375175 DOI: 10.2174/0929867328666210810124159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 06/18/2021] [Accepted: 06/29/2021] [Indexed: 11/22/2022]
Abstract
This review intends to summarize the structures of an extensive number of symmetrical-dimeric drugs, having two monomers linked via a bridging entity while emphasizing the large versatility of biologically active substances reported to possess dimeric structures. The largest number of classes of these compounds consist of anticancer agents, antibiotics/antimicrobials, and anti-AIDS drugs. Other symmetrical-dimeric drugs include antidiabetics, antidepressants, analgesics, anti-inflammatories, drugs for the treatment of Alzheimer's disease, anticholesterolemics, estrogenics, antioxidants, enzyme inhibitors, anti-Parkisonians, laxatives, antiallergy compounds, cannabinoids, etc. Most of the articles reviewed do not compare the activity/potency of the dimers to that of their corresponding monomers. Only in limited cases, various suggestions have been made to justify unexpected higher activity of the dimers vs. the corresponding monomers. These suggestions include statistical effects, the presence of dimeric receptors, binding of a dimer to two receptors simultaneously, and others. It is virtually impossible to predict which dimers will be preferable to their respective monomers, or which linking bridges will lead to the most active compounds. It is expected that the extensive number of articles summarized, and the large variety of substances mentioned, which display various biological activities, should be of interest to many academic and industrial medicinal chemists.
Collapse
Affiliation(s)
- Abraham Nudelman
- Chemistry Department, Bar Ilan University, Ramat Gan 52900, Israel
| |
Collapse
|
9
|
Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase. Biophys J 2020; 119:2275-2289. [PMID: 33130120 DOI: 10.1016/j.bpj.2020.10.024] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 10/08/2020] [Accepted: 10/21/2020] [Indexed: 12/18/2022] Open
Abstract
Influenza neuraminidase is an important drug target. Glycans are present on neuraminidase and are generally considered to inhibit antibody binding via their glycan shield. In this work, we studied the effect of glycans on the binding kinetics of antiviral drugs to the influenza neuraminidase. We created all-atom in silico systems of influenza neuraminidase with experimentally derived glycoprofiles consisting of four systems with different glycan conformations and one system without glycans. Using Brownian dynamics simulations, we observe a two- to eightfold decrease in the rate of ligand binding to the primary binding site of neuraminidase due to the presence of glycans. These glycans are capable of covering much of the surface area of neuraminidase, and the ligand binding inhibition is derived from glycans sterically occluding the primary binding site on a neighboring monomer. Our work also indicates that drugs preferentially bind to the primary binding site (i.e., the active site) over the secondary binding site, and we propose a binding mechanism illustrating this. These results help illuminate the complex interplay between glycans and ligand binding on the influenza membrane protein neuraminidase.
Collapse
|
10
|
Shie JJ, Fang JM. Development of effective anti-influenza drugs: congeners and conjugates - a review. J Biomed Sci 2019; 26:84. [PMID: 31640786 PMCID: PMC6806523 DOI: 10.1186/s12929-019-0567-0] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 09/16/2019] [Indexed: 12/20/2022] Open
Abstract
Influenza is a long-standing health problem. For treatment of seasonal flu and possible pandemic infections, there is a need to develop new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses, including the resistant strains. Relenza™ (zanamivir), Tamiflu™ (the phosphate salt of oseltamivir), Inavir™ (laninamivir octanoate) and Rapivab™ (peramivir) are four anti-influenza drugs targeting the viral neuraminidases (NAs). However, some problems of these drugs should be resolved, such as oral availability, drug resistance and the induced cytokine storm. Two possible strategies have been applied to tackle these problems by devising congeners and conjugates. In this review, congeners are the related compounds having comparable chemical structures and biological functions, whereas conjugate refers to a compound having two bioactive entities joined by a covalent bond. The rational design of NA inhibitors is based on the mechanism of the enzymatic hydrolysis of the sialic acid (Neu5Ac)-terminated glycoprotein. To improve binding affinity and lipophilicity of the existing NA inhibitors, several methods are utilized, including conversion of carboxylic acid to ester prodrug, conversion of guanidine to acylguanidine, substitution of carboxylic acid with bioisostere, and modification of glycerol side chain. Alternatively, conjugating NA inhibitors with other therapeutic entity provides a synergistic anti-influenza activity; for example, to kill the existing viruses and suppress the cytokines caused by cross-species infection.
Collapse
Affiliation(s)
- Jiun-Jie Shie
- Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan
| | - Jim-Min Fang
- Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan. .,The Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan.
| |
Collapse
|
11
|
Divalent oseltamivir analogues as potent influenza neuraminidase inhibitors. Carbohydr Res 2019; 477:32-38. [DOI: 10.1016/j.carres.2019.03.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 03/21/2019] [Accepted: 03/28/2019] [Indexed: 11/23/2022]
|
12
|
Jiang X, Yu J, Zhou Z, Kongsted J, Song Y, Pannecouque C, De Clercq E, Kang D, Poongavanam V, Liu X, Zhan P. Molecular design opportunities presented by solvent‐exposed regions of target proteins. Med Res Rev 2019; 39:2194-2238. [DOI: 10.1002/med.21581] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2018] [Revised: 03/09/2019] [Accepted: 03/16/2019] [Indexed: 12/24/2022]
Affiliation(s)
- Xiangyi Jiang
- Department of Medicinal ChemistryKey Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan Shandong People's Republic of China
| | - Ji Yu
- Department of Medicinal ChemistryKey Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan Shandong People's Republic of China
| | - Zhongxia Zhou
- Department of Medicinal ChemistryKey Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan Shandong People's Republic of China
| | - Jacob Kongsted
- Department of Physics, Chemistry and PharmacyUniversity of Southern Denmark Odense Denmark
| | - Yuning Song
- Department of Clinical PharmacyQilu Hospital of Shandong University Jinan China
| | - Christophe Pannecouque
- Rega Institute for Medical ResearchLaboratory of Virology and Chemotherapy Leuven Belgium
| | - Erik De Clercq
- Rega Institute for Medical ResearchLaboratory of Virology and Chemotherapy Leuven Belgium
| | - Dongwei Kang
- Department of Medicinal ChemistryKey Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan Shandong People's Republic of China
| | | | - Xinyong Liu
- Department of Medicinal ChemistryKey Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan Shandong People's Republic of China
| | - Peng Zhan
- Department of Medicinal ChemistryKey Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan Shandong People's Republic of China
| |
Collapse
|
13
|
Compain P. Multivalent Effect in Glycosidase Inhibition: The End of the Beginning. CHEM REC 2019; 20:10-22. [PMID: 30993894 DOI: 10.1002/tcr.201900004] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 03/15/2019] [Indexed: 12/21/2022]
Abstract
Glycosidases are ubiquitous enzymes involved in a diversity of key biological processes such as energy uptake or cell wall degradation. The design of specific glycosidase inhibitors has been therefore the subject of intense research efforts in academia and pharmaceutical industry. However, until recently, the study of the impact of multivalency on glycosidase inhibition was almost completely neglected. The following account will review our ten year journey on the design of multivalent glycomimetics within our research group, from the discovery of the first strong multivalent effect in glycosidase inhibition to the high-resolution crystal structures of Jack bean α-mannosidase in complex with the multimeric inhibitor displaying the largest binding enhancements reported so far.
Collapse
Affiliation(s)
- Philippe Compain
- Laboratoire d'Innovation Moléculaire et Applications (LIMA), Univ. de Strasbourg, Univ. de Haute-Alsace, CNRS (UMR 7042), Equipe de Synthèse Organique et Molécules Bioactives (SYBIO), ECPM, 25 Rue Becquerel, 67000, Strasbourg, France
| |
Collapse
|
14
|
Brissonnet Y, Assailly C, Saumonneau A, Bouckaert J, Maillasson M, Petitot C, Roubinet B, Didak B, Landemarre L, Bridot C, Blossey R, Deniaud D, Yan X, Bernard J, Tellier C, Grandjean C, Daligault F, Gouin SG. Multivalent Thiosialosides and Their Synergistic Interaction with Pathogenic Sialidases. Chemistry 2019; 25:2358-2365. [DOI: 10.1002/chem.201805790] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 12/03/2018] [Indexed: 01/18/2023]
Affiliation(s)
- Yoan Brissonnet
- CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation; UMR CNRS 6230; UFR des Sciences et des Techniques; Université de Nantes; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Coralie Assailly
- CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation; UMR CNRS 6230; UFR des Sciences et des Techniques; Université de Nantes; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Amélie Saumonneau
- UFR des Sciences et des Techniques; Université de Nantes, UFIP, UMR CNRS 6286; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Julie Bouckaert
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 CNRS; Université de Lille 1; Lille 59000 France
| | - Mike Maillasson
- Impact biogeneouest; CRCINA; Inserm; CNRS; Université de Nantes; Nantes France
| | - Clémence Petitot
- UFR des Sciences et des Techniques; Université de Nantes, UFIP, UMR CNRS 6286; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Benoit Roubinet
- Bâtiment Physique-Chimie; Glycodiag; Rue de Chartres, BP6759 45067 Orléans cedex 2 France
| | - Blanka Didak
- Bâtiment Physique-Chimie; Glycodiag; Rue de Chartres, BP6759 45067 Orléans cedex 2 France
| | - Ludovic Landemarre
- Bâtiment Physique-Chimie; Glycodiag; Rue de Chartres, BP6759 45067 Orléans cedex 2 France
| | - Clarisse Bridot
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 CNRS; Université de Lille 1; Lille 59000 France
| | - Ralf Blossey
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 CNRS; Université de Lille 1; Lille 59000 France
| | - David Deniaud
- CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation; UMR CNRS 6230; UFR des Sciences et des Techniques; Université de Nantes; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Xibo Yan
- Université de Lyon, Lyon; 69003 (France), INSA- Lyon, IMP, Villeurbanne, 69621, France, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Villeurbanne, 69621 France
| | - Julien Bernard
- Université de Lyon, Lyon; 69003 (France), INSA- Lyon, IMP, Villeurbanne, 69621, France, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Villeurbanne, 69621 France
| | - Charles Tellier
- UFR des Sciences et des Techniques; Université de Nantes, UFIP, UMR CNRS 6286; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Cyrille Grandjean
- UFR des Sciences et des Techniques; Université de Nantes, UFIP, UMR CNRS 6286; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Franck Daligault
- UFR des Sciences et des Techniques; Université de Nantes, UFIP, UMR CNRS 6286; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| | - Sébastien G. Gouin
- CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation; UMR CNRS 6230; UFR des Sciences et des Techniques; Université de Nantes; 2 rue de la Houssinière, BP 92208 44322 Nantes Cedex 3 France
| |
Collapse
|
15
|
Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Am J Cancer Res 2017; 7:826-845. [PMID: 28382157 PMCID: PMC5381247 DOI: 10.7150/thno.17071] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Accepted: 11/18/2016] [Indexed: 02/05/2023] Open
Abstract
The influenza pandemic is a major threat to human health, and highly aggressive strains such as H1N1, H5N1 and H7N9 have emphasized the need for therapeutic strategies to combat these pathogens. Influenza anti-viral agents, especially active small molecular inhibitors play important roles in controlling pandemics while vaccines are developed. Currently, only a few drugs, which function as influenza neuraminidase (NA) inhibitors and M2 ion channel protein inhibitors, are approved in clinical. However, the acquired resistance against current anti-influenza drugs and the emerging mutations of influenza virus itself remain the major challenging unmet medical needs for influenza treatment. It is highly desirable to identify novel anti-influenza agents. This paper reviews the progress of small molecular inhibitors act as antiviral agents, which include hemagglutinin (HA) inhibitors, RNA-dependent RNA polymerase (RdRp) inhibitors, NA inhibitors and M2 ion channel protein inhibitors etc. Moreover, we also summarize new, recently reported potential targets and discuss strategies for the development of new anti-influenza virus drugs.
Collapse
|
16
|
Yu Y, Zheng J, Cao L, Li S, Li X, Zhou HB, Liu X, Wu S, Dong C. Furan-carboxamide derivatives as novel inhibitors of lethal H5N1 influenza A viruses. RSC Adv 2017. [DOI: 10.1039/c7ra00305f] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The simple scaffold furan-carboxamide derivatives were firstly identified as novel inhibitors of lethal H5N1 influenza A virus.
Collapse
Affiliation(s)
- Yongshi Yu
- Hubei Provincial Key Laboratory of Developmentally Originated Disease
- Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| | - Jie Zheng
- Hubei Provincial Key Laboratory of Developmentally Originated Disease
- Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| | - Lei Cao
- State Key Laboratory of Virology
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
| | - Shu Li
- Medical Research Institute
- Wuhan University
- Wuhan 430071
- China
| | - Xiwang Li
- Hubei Provincial Key Laboratory of Developmentally Originated Disease
- Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| | - Hai-Bing Zhou
- Hubei Provincial Key Laboratory of Developmentally Originated Disease
- Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| | | | - Shuwen Wu
- State Key Laboratory of Virology
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
| | - Chune Dong
- Hubei Provincial Key Laboratory of Developmentally Originated Disease
- Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| |
Collapse
|
17
|
Fu L, Bi Y, Wu Y, Zhang S, Qi J, Li Y, Lu X, Zhang Z, Lv X, Yan J, Gao GF, Li X. Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses. J Med Chem 2016; 59:6303-12. [DOI: 10.1021/acs.jmedchem.6b00537] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Lifeng Fu
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
- National
Engineering Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, China
- Graduate
University of Chinese Academy of Sciences, Shijingshan District, Beijing 100049, China
| | - Yuhai Bi
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
| | - Yan Wu
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
| | - Shanshan Zhang
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
- Graduate
University of Chinese Academy of Sciences, Shijingshan District, Beijing 100049, China
| | - Jianxun Qi
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
| | - Yan Li
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
| | - Xuancheng Lu
- Laboratory
Animal Center, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, China
| | - Zhenning Zhang
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
- Graduate
University of Chinese Academy of Sciences, Shijingshan District, Beijing 100049, China
| | - Xun Lv
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
| | - Jinghua Yan
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
- Center
for Influenza Research and Early Warning, Chinese Academy of Sciences (CASCIRE), Chaoyang District, Beijing 100101, China
| | - George F. Gao
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
- Center
for Influenza Research and Early Warning, Chinese Academy of Sciences (CASCIRE), Chaoyang District, Beijing 100101, China
| | - Xuebing Li
- CAS
Key Laboratory of Pathogenic Microbiology and Immunology, Institute
of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China
- National
Engineering Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, China
- Center
for Influenza Research and Early Warning, Chinese Academy of Sciences (CASCIRE), Chaoyang District, Beijing 100101, China
| |
Collapse
|
18
|
Brissonnet Y, Ladevèze S, Tezé D, Fabre E, Deniaud D, Daligault F, Tellier C, Šesták S, Remaud-Simeon M, Potocki-Veronese G, Gouin SG. Polymeric Iminosugars Improve the Activity of Carbohydrate-Processing Enzymes. Bioconjug Chem 2015; 26:766-72. [DOI: 10.1021/acs.bioconjchem.5b00081] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Yoan Brissonnet
- LUNAM
Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse,
Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Simon Ladevèze
- Laboratoire
d’Ingénierie des Systèmes Biologiques et des
Procédés, Institut National des Sciences Appliquées, CNRS UMR5504, Institut National de Recherche Agronomique, UMR792, 135 Ave. de Rangueil, 31077 Toulouse, France
| | - David Tezé
- LUNAM
Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse,
Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Emeline Fabre
- Université
Lille 1, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576, 59650 Villeneuve d’Ascq, France
| | - David Deniaud
- LUNAM
Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse,
Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Franck Daligault
- UFIP,
UMR CNRS 6286, Faculté des Sciences et Techniques, Université de Nantes, 2 rue de la Houssinière, F-44322 Nantes, France
| | - Charles Tellier
- UFIP,
UMR CNRS 6286, Faculté des Sciences et Techniques, Université de Nantes, 2 rue de la Houssinière, F-44322 Nantes, France
| | - Sergej Šesták
- Institute
of Chemistry, Center for Glycomics, Slovak Academy of Sciences, Dúbravska cesta 9, 845 38 Bratislava, Slovakia
| | - Magali Remaud-Simeon
- Laboratoire
d’Ingénierie des Systèmes Biologiques et des
Procédés, Institut National des Sciences Appliquées, CNRS UMR5504, Institut National de Recherche Agronomique, UMR792, 135 Ave. de Rangueil, 31077 Toulouse, France
| | - Gabrielle Potocki-Veronese
- Laboratoire
d’Ingénierie des Systèmes Biologiques et des
Procédés, Institut National des Sciences Appliquées, CNRS UMR5504, Institut National de Recherche Agronomique, UMR792, 135 Ave. de Rangueil, 31077 Toulouse, France
| | - Sébastien G. Gouin
- LUNAM
Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse,
Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| |
Collapse
|
19
|
From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Future Med Chem 2015; 6:757-74. [PMID: 24941871 DOI: 10.4155/fmc.14.30] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
For the treatment of seasonal flu and possible pandemic infections the development of new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses including the resistant strains is needed. In this review, we summarize previous methods for the structural modification of zanamivir, a potent neuraminidase inhibitor that has rare drug resistance, in order to develop effective anti-influenza drugs. We also report recent research into the design of multivalent zanamivir drugs and bifunctional zanamivir conjugates, some of which have shown better efficacy in animal experiments. As a step towards developing improved antivirals, conjugating anti-influenza drugs with anti-inflammatory agents can improve oral bioavailability and also exert synergistic effect in influenza therapy.
Collapse
|
20
|
Kanfar N, Bartolami E, Zelli R, Marra A, Winum JY, Ulrich S, Dumy P. Emerging trends in enzyme inhibition by multivalent nanoconstructs. Org Biomol Chem 2015; 13:9894-906. [DOI: 10.1039/c5ob01405k] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
This review highlights the recent implementation of multivalent nanoconstructs in enzyme inhibition and discusses the emerging trends in their design and identification.
Collapse
Affiliation(s)
- Nasreddine Kanfar
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| | - Eline Bartolami
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| | - Renaud Zelli
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| | - Alberto Marra
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| | - Jean-Yves Winum
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| | - Sébastien Ulrich
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| | - Pascal Dumy
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247 CNRS
- Université Montpellier
- ENSCM
- Ecole Nationale Supérieure de Chimie de Montpellier
| |
Collapse
|
21
|
Antiviral Drugs for Influenza and Other Respiratory Virus Infections. MANDELL, DOUGLAS, AND BENNETT'S PRINCIPLES AND PRACTICE OF INFECTIOUS DISEASES 2015. [PMCID: PMC7152365 DOI: 10.1016/b978-1-4557-4801-3.00044-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
22
|
Abellán-Flos M, Tanç M, Supuran CT, Vincent SP. Exploring carbonic anhydrase inhibition with multimeric coumarins displayed on a fullerene scaffold. Org Biomol Chem 2015; 13:7445-51. [DOI: 10.1039/c5ob01005e] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
This study reports the first synthesis of multimeric suicide inhibitors of carbonic anhydrases.
Collapse
Affiliation(s)
- Marta Abellán-Flos
- University of Namur (UNamur)
- Académie Louvain
- Département de Chimie
- Laboratoire de Chimie Bio-Organique
- B-5000 Namur
| | - Muhammet Tanç
- Università degli Studi di Firenze
- Polo Scientifico
- Laboratorio di Chimica Bioinorganica
- Florence
- Italy
| | - Claudiu T. Supuran
- Università degli Studi di Firenze
- Polo Scientifico
- Laboratorio di Chimica Bioinorganica
- Florence
- Italy
| | - Stéphane P. Vincent
- University of Namur (UNamur)
- Académie Louvain
- Département de Chimie
- Laboratoire de Chimie Bio-Organique
- B-5000 Namur
| |
Collapse
|
23
|
Loregian A, Mercorelli B, Nannetti G, Compagnin C, Palù G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci 2014; 71:3659-83. [PMID: 24699705 PMCID: PMC11114059 DOI: 10.1007/s00018-014-1615-2] [Citation(s) in RCA: 132] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 03/04/2014] [Accepted: 03/18/2014] [Indexed: 01/02/2023]
Abstract
Influenza viruses are major human pathogens responsible for respiratory diseases affecting millions of people worldwide and characterized by high morbidity and significant mortality. Influenza infections can be controlled by vaccination and antiviral drugs. However, vaccines need annual updating and give limited protection. Only two classes of drugs are currently approved for the treatment of influenza: M2 ion channel blockers and neuraminidase inhibitors. However, they are often associated with limited efficacy and adverse side effects. In addition, the currently available drugs suffer from rapid and extensive emergence of drug resistance. All this highlights the urgent need for developing new antiviral strategies with novel mechanisms of action and with reduced drug resistance potential. Several new classes of antiviral agents targeting viral replication mechanisms or cellular proteins/processes are under development. This review gives an overview of novel strategies targeting the virus and/or the host cell for counteracting influenza virus infection.
Collapse
Affiliation(s)
- Arianna Loregian
- Department of Molecular Medicine, University of Padua, via Gabelli 63, 35121, Padua, Italy,
| | | | | | | | | |
Collapse
|
24
|
Gouin SG. Multivalent Inhibitors for Carbohydrate-Processing Enzymes: Beyond the “Lock-and-Key” Concept. Chemistry 2014; 20:11616-28. [DOI: 10.1002/chem.201402537] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
25
|
Compain P, Bodlenner A. The Multivalent Effect in Glycosidase Inhibition: A New, Rapidly Emerging Topic in Glycoscience. Chembiochem 2014; 15:1239-51. [DOI: 10.1002/cbic.201402026] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Indexed: 11/07/2022]
|
26
|
|
27
|
Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. J Antimicrob Chemother 2014; 69:2164-74. [PMID: 24777908 DOI: 10.1093/jac/dku127] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVES Emerging drug resistance to antiviral therapies is an increasing challenge for the treatment of influenza virus infections. One new antiviral compound, BTA938, a dimeric derivative of the viral neuraminidase inhibitor zanamivir, contains a 14-carbon linker bridging two zanamivir moieties. In these studies, we evaluated antiviral efficacy in cell cultures infected with influenza virus and in mouse models of lethal influenza using H1N1pdm09, H3N2 and oseltamivir-resistant (H275Y) viruses. METHODS In vitro activity was evaluated against 22 strains of influenza virus. Additionally, in vivo studies compared the efficacy of BTA938 or zanamivir after intranasal treatment. We also tested the hypothesis of a dual mode of action for BTA938 using scanning electron microscopy (SEM). RESULTS BTA938 inhibited the viruses at nanomolar concentrations in vitro with a median 50% effective concentration value of 0.5 nM. In mouse models, the dimer provided ∼10-fold greater protection than zanamivir. The data also showed that a single low dose (3 mg/kg) protected 100% of mice from an otherwise lethal oseltamivir-resistant (H275Y) influenza virus infection. Remarkably, a single prophylactic treatment (10 mg/kg) administered 7 days before the challenge protected 70% of mice and when administered 1 or 3 days before the challenge it protected 90% of mice. Additionally, SEM provides evidence that the increased antiviral potency may be mediated by an enhanced aggregation of virus on the cell surface. CONCLUSIONS In vitro and in vivo experiments showed the high antiviral activity of BTA938 for the treatment of influenza virus infections. Moreover, we demonstrated that a single dose of BTA938 is sufficient for prophylactic and therapeutic protection in mouse models.
Collapse
Affiliation(s)
- E Bart Tarbet
- Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | | | - Almut H Vollmer
- Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | | | - Wy Ching Ng
- Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia
| | | | - Brett L Hurst
- Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | - Simon Crawford
- School of Botany, University of Melbourne, Parkville, Australia
| | - Donald F Smee
- Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
| | | |
Collapse
|
28
|
Rísquez‐Cuadro R, García Fernández JM, Nierengarten J, Ortiz Mellet C. Fullerene‐sp
2
‐Iminosugar Balls as Multimodal Ligands for Lectins and Glycosidases: A Mechanistic Hypothesis for the Inhibitory Multivalent Effect. Chemistry 2013; 19:16791-803. [DOI: 10.1002/chem.201303158] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Indexed: 01/25/2023]
Affiliation(s)
- Rocío Rísquez‐Cuadro
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, C/Prof. García González 1, 41012 Sevilla (Spain)
| | - José M. García Fernández
- Instituto de Investigaciones Químicas (IIQ), CSIC ‐ Universidad de Sevilla, Av. Américo Vespucio 49, Isla de la Cartuja, 41092 Sevilla (Spain)
| | - Jean‐François Nierengarten
- Laboratoire de Chimie des Matériaux Moléculaires, Université de Strasbourg et CNRS (UMR 7509), Ecole Européenne de Chimie, Polymères et Matériaux, 25 rue Becquerel, 67087 Strasbourg (France)
| | - Carmen Ortiz Mellet
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, C/Prof. García González 1, 41012 Sevilla (Spain)
| |
Collapse
|
29
|
McKimm-Breschkin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, Saito T, Tashiro M. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother 2013; 68:2210-21. [PMID: 23759505 DOI: 10.1093/jac/dkt205] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES We characterized human H1N1 influenza isolate A/Hokkaido/15/02, which has haemagglutinin and neuraminidase mutations that reduce drug susceptibility to oseltamivir, zanamivir and peramivir. METHODS One wild-type and three mutant viruses were isolated by plaque purification. Viruses were tested in MUNANA-based enzyme assays, cell culture and receptor binding assays. RESULTS Two viruses had a neuraminidase Y155H mutation that reduced susceptibility in the enzyme inhibition assay to all inhibitors by 30-fold to >100-fold. The Y155H mutation reduced plaque size and affected the stability, Km and pH activity profile of the enzyme. In contrast to previous mutants, this neuraminidase demonstrated a slower rate of inhibitor binding in the IC50 kinetics assay. One virus had both the Y155H mutation and a haemagglutinin D225G mutation that rescued the small-plaque phenotype of the Y155H virus and affected receptor binding and drug susceptibility in cell culture and binding assays. We also isolated a third mutant virus, with both neuraminidase V114I and haemagglutinin D225N mutations, which affected susceptibility in the enzyme inhibition assay and receptor binding, respectively, but to lesser extents than the Y155H and D225G mutations. CONCLUSIONS Neither Y155 nor V114 is conserved across neuraminidase subtypes. Furthermore, Y155 is not conserved even among avian and swine N1 viruses. Structurally, both residues reside far from the neuraminidase active site. D225 forms part of the receptor binding site of the haemagglutinin. We believe this is the first demonstration of a specific haemagglutinin mutation correlating with reduced drug susceptibility in plaque assays in both Madin Darby Canine Kidney and SIAT cells.
Collapse
|
30
|
Biernatowska A, Podkalicka J, Majkowski M, Hryniewicz-Jankowska A, Augoff K, Kozak K, Korzeniewski J, Sikorski AF. The role of MPP1/p55 and its palmitoylation in resting state raft organization in HEL cells. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2013; 1833:1876-84. [PMID: 23507198 DOI: 10.1016/j.bbamcr.2013.03.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2012] [Revised: 01/31/2013] [Accepted: 03/04/2013] [Indexed: 12/24/2022]
Abstract
Here we show the crucial role of MPP1 in lateral membrane ordering/organization in HEL cells (derived from erythroid precursors). Biochemical analyses showed that inhibition of MPP1 palmitoylation or silencing of the MPP1 gene led to a dramatic decrease in the DRM fraction. This was accompanied by a reduction of membrane order as shown by fluorescence-lifetime imaging microscopy (FLIM) analyses. Furthermore, MPP1 knockdown significantly affects the activation of MAP-kinase signaling via raft-dependent RTK (receptor tyrosine kinase) receptors, indicating the importance of MPP1 for lateral membrane organization. In conclusion, palmitoylation of MPP1 appears to be at least one of the mechanisms controlling lateral organization of the erythroid cell membrane. Thus, this study, together with our recent results on erythrocytes, reported elsewhere (Łach et al., J. Biol. Chem., 2012, 287, 18974-18984), points to a new role for MPP1 and presents a novel linkage between membrane raft organization and protein palmitoylation.
Collapse
|
31
|
Chamni S, De-Eknamkul W. Recent progress and challenges in the discovery of new neuraminidase inhibitors. Expert Opin Ther Pat 2013; 23:409-23. [DOI: 10.1517/13543776.2013.765861] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
32
|
Feng E, Shin WJ, Zhu X, Li J, Ye D, Wang J, Zheng M, Zuo JP, No KT, Liu X, Zhu W, Tang W, Seong BL, Jiang H, Liu H. Structure-Based Design and Synthesis of C-1- and C-4-Modified Analogs of Zanamivir as Neuraminidase Inhibitors. J Med Chem 2013; 56:671-84. [DOI: 10.1021/jm3009713] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Enguang Feng
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Woo-Jin Shin
- Department
of Biotechnology,
College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea
| | - Xuelian Zhu
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Jian Li
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Deju Ye
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Jiang Wang
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Mingyue Zheng
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Jian-Ping Zuo
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Kyoung Tai No
- Department
of Biotechnology,
College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea
| | - Xian Liu
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Weiliang Zhu
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Wei Tang
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Baik-Lin Seong
- Department
of Biotechnology,
College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea
| | - Hualiang Jiang
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| | - Hong Liu
- State Key Laboratory of Drug
Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu chong zhi Road, Shanghai
201203, China
| |
Collapse
|
33
|
Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 2013; 7 Suppl 1:63-75. [PMID: 23279899 PMCID: PMC5978626 DOI: 10.1111/irv.12045] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
This summary provides an overview of investigational antiviral agents for influenza and of future directions for development of influenza therapeutics. While progress in developing clinically useful antiviral agents for influenza has been generally slow, especially with respect to seriously ill and high-risk patients, important clinical studies of intravenous neuraminidase inhibitors, antibodies and drug combinations are currently in progress. The current decade offers the promise of developing small molecular weight inhibitors with novel mechanisms of action, including host-directed therapies, new biotherapeutics and drug combinations, that should provide more effective antiviral therapies and help mitigate the problem of antiviral resistance. Immunomodulatory interventions also offer promise but need to be based on better understanding of influenza pathogenesis, particularly in seriously ill patients. The development of combination interventions, immunomodulators and host-directed therapies presents unique clinical trial design and regulatory hurdles that remain to be addressed.
Collapse
Affiliation(s)
- Frederick G Hayden
- Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.
| |
Collapse
|
34
|
Fraser BH, Hamilton S, Krause-Heuer AM, Wright PJ, Greguric I, Tucker SP, Draffan AG, Fokin VV, Sharpless KB. Synthesis of 1,4-triazole linked zanamivir dimers as highly potent inhibitors of influenza A and B. MEDCHEMCOMM 2013. [DOI: 10.1039/c2md20300f] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
35
|
Hayakawa M, Toda N, Carrillo N, Thornburg NJ, Crowe JE, Barbas CF. A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase. Chembiochem 2012; 13:2191-5. [PMID: 22965667 PMCID: PMC3517015 DOI: 10.1002/cbic.201200439] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2012] [Indexed: 11/10/2022]
Abstract
Programming an anti-flu strategy: A new and potent neuraminidase inhibitor that maintains long-term systemic exposure of an antibody and the therapeutic activity of the neuraminadase inhibitor zanamivir has been created. This strategy could provide a promising new class of influenza A drugs for therapy and prophylaxis, and validates enzyme inhibitors as programming agents in synthetic immunology.
Collapse
Affiliation(s)
- Masahiko Hayakawa
- Departments of Chemistry, Molecular Biology, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North, Torrey Pines Road, La Jolla, CA 92037 (USA)
| | - Narihiro Toda
- Departments of Chemistry, Molecular Biology, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North, Torrey Pines Road, La Jolla, CA 92037 (USA)
| | - Nancy Carrillo
- Departments of Chemistry, Molecular Biology, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North, Torrey Pines Road, La Jolla, CA 92037 (USA)
| | - Natalie J. Thornburg
- Departments of Pediatrics, Pathology, Microbiology and Immunology, and Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV - 2213 Garland Ave. Nashville, TN 37232-0417
| | - James E. Crowe
- Departments of Pediatrics, Pathology, Microbiology and Immunology, and Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV - 2213 Garland Ave. Nashville, TN 37232-0417
| | - Carlos F. Barbas
- Departments of Chemistry, Molecular Biology, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North, Torrey Pines Road, La Jolla, CA 92037 (USA)
| |
Collapse
|
36
|
Ye D, Shin WJ, Li N, Tang W, Feng E, Li J, He PL, Zuo JP, Kim H, Nam KY, Zhu W, Seong BL, Tai No K, Jiang H, Liu H. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. Eur J Med Chem 2012; 54:764-70. [DOI: 10.1016/j.ejmech.2012.06.033] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Revised: 06/11/2012] [Accepted: 06/15/2012] [Indexed: 01/16/2023]
|
37
|
Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem 2012; 7:1527-36. [PMID: 22807317 DOI: 10.1002/cmdc.201200155] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2012] [Revised: 06/13/2012] [Indexed: 11/06/2022]
Abstract
The recent emergence of the highly pathogenic H5N1 subtype of avian influenza virus (AIV) and of the new type of human influenza A (H1N1) have emphasized the need for the development of effective anti-influenza drugs. Presently, neuraminidase (NA) inhibitors are widely used in the treatment and prophylaxis of human influenza virus infection, and tremendous efforts have been made to develop more potent NA inhibitors to combat resistance and new influenza viruses. In this review, we discuss the structural characteristics of NA catalytic domains and the recent developments of new NA inhibitors using structure-based drug design strategies. These drugs include analogues of zanamivir, analogues of oseltamivir, analogues of peramivir, and analogues of aromatic carboxylic acid and present promising options for therapeutics or leads for further development of NA inhibitors that may be useful in the event of a future influenza pandemic.
Collapse
Affiliation(s)
- Enguang Feng
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Graduate School of the Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM. Influenza neuraminidase: A druggable target for natural products. Nat Prod Rep 2012; 29:11-36. [DOI: 10.1039/c1np00053e] [Citation(s) in RCA: 116] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
39
|
A perspective on synthetic and solid-form enablement of inhalation candidates. Future Med Chem 2011; 3:1679-701. [DOI: 10.4155/fmc.11.125] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
The administration of compounds by a dry-powder inhaler presents significant challenges to the development and discovery chemist, owing to the stringent requirements placed upon the physical characteristics of the active pharmaceutical ingredient and the high complexity of the molecules concerned. The current state of synthetic chemistry technology is such that commercial syntheses of these compounds are demanding but achievable. While synthetic chemistry will remain a major component of the development of inhaled therapies, the main challenge facing practitioners in this area is the early identification of a suitable solid form. Further advances in the prediction of solid-form properties would significantly enable this field and may allow triage of molecules to be carried out at the design stage of projects.
Collapse
|
40
|
Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2011; 15:1151-9. [PMID: 21149922 DOI: 10.3851/imp1678] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010. METHODS Virus isolates were tested for adamantane susceptibility, using pyrosequencing to detect the S31N marker of adamantane resistance in the M2 protein and biological assays to assess viral replication in cell culture. To assess neuraminidase (NA) inhibitor (NAI) susceptibility, virus isolates were tested in chemiluminescent NA inhibition assays and by pyrosequencing to detect the H275Y (H274Y in N2 numbering) marker of oseltamivir resistance in the NA. RESULTS With the exception of three, all viruses that were tested for adamantane susceptibility (n=3,362) were resistant to this class of drugs. All viruses tested for NAI susceptibility (n=3,359) were sensitive to two US Food and Drug Administration-approved NAIs, oseltamivir (mean ±sd 50% inhibitory concentration [IC(50)] 0.25 ±0.12 nM) and zanamivir (mean IC(50) 0.29 ±0.09 nM), except 23 (0.7%), which were resistant to oseltamivir, but sensitive to zanamivir. Oseltamivir-resistant viruses had the H275Y mutation in their NA and were detected in patients exposed to the drug through prophylaxis or treatment. NA activity of all viruses was inhibited by the NAIs peramivir, laninamivir (R-125489) and A-315675, except for H275Y variants, which exhibited approximately 100-fold reduction in peramivir susceptibility. CONCLUSIONS This report provides data regarding antiviral susceptibility of 2009 pandemic influenza A (H1N1) surveillance viruses, the majority of which were resistant to adamantanes and sensitive to NAIs. These findings provide information essential for antiviral resistance monitoring and development of novel diagnostic tests for detecting influenza antiviral resistance.
Collapse
Affiliation(s)
- Larisa V Gubareva
- Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Preziosi P. Influenza pharmacotherapy: present situation, strategies and hopes. Expert Opin Pharmacother 2011; 12:1523-49. [PMID: 21438743 DOI: 10.1517/14656566.2011.566557] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Influenza is a serious health threat for people of all ages. The causative virus is evolving continuously and the risk of an unexpected mutant, which cannot be controlled by seasonal vaccination, is real. New and more effective antiviral drugs are needed. AREAS COVERED This review examines the antiviral drugs with confirmed efficacy in combating influenza, as well as newer compounds that are currently undergoing testing and will hopefully be marketed in the near future. A comprehensive, state-of-the-art picture of drug therapy for influenza is presented, including novel solutions and effective strategies for prescribing currently available antiviral drugs, with emphasis on the importance of updated local epidemiological data, clinical assessment and laboratory testing. EXPERT OPINION Current anti-influenza drug research is no longer tied solely to viral envelope protein targets like haemagglutinin and neuraminidase. New drugs act on the viral RNA polymerase complex, which is involved in transcription and replication of the viral genome, and can prevent the maturation, replication and dissemination of numerous viral subtypes. Combating this infection and reducing the duration of symptoms also has important socioeconomic implications related to health-care spending (including hospitalization for complications) and sick-leave pay for workers.
Collapse
Affiliation(s)
- Paolo Preziosi
- Emeritus of Pharmacology, Catholic University School of Medicine, Institute of Pharmacology, Largo Francesco Vito, 1 00168 Rome, Italy.
| |
Collapse
|
42
|
Stanley M, Martin SR, Birge M, Carbain B, Streicher H. Biotin-, fluorescein- and ‘clickable’ conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase. Org Biomol Chem 2011; 9:5625-9. [DOI: 10.1039/c1ob05384a] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
43
|
Wen WH, Lin M, Su CY, Wang SY, Cheng YSE, Fang JM, Wong CH. Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus. J Med Chem 2009; 52:4903-10. [PMID: 19522501 DOI: 10.1021/jm900515g] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
New anti-influenza agents of tetravalent zanamivir on a porphyrin scaffold were synthesized. These compounds are 10 to 100 times more potent in inhibiting influenza replications even though they are somewhat less potent in neuraminidase inhibition than the monomeric zanamivir. The enhanced anti-influenza activity is probably attributable to the additional viral inactivation by singlet oxygen due to sensitization of the porphyrin moiety, which is brought in close proximity of virus by the conjugated zanamivir in a manner resembling the "magic bullet" mechanism.
Collapse
Affiliation(s)
- Wen-Hsien Wen
- Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan
| | | | | | | | | | | | | |
Collapse
|
44
|
Magano J. Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza. Chem Rev 2009; 109:4398-438. [DOI: 10.1021/cr800449m] [Citation(s) in RCA: 185] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Javier Magano
- Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340
| |
Collapse
|
45
|
Weïwer M, Chen CC, Kemp MM, Linhardt RJ. Synthesis and Biological Evaluation of Non-Hydrolizable 1,2,3-Triazole Linked Sialic Acid Derivatives as Neuraminidase Inhibitors. European J Org Chem 2009; 2009. [PMID: 24223493 DOI: 10.1002/ejoc.200900117] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
α-Sialic acid azide 1 has been used as a substrate for the efficient preparation of 1,2,3-triazole derivatives of sialic acid using the copper-catalyzed azide-alkyne Huisgen cycloaddition ("click chemistry"). Our approach is to generate non-natural N-glycosides of sialic acid that are resistant to neuraminidase catalyzed hydrolysis as opposed to the natural O-glycosides. These N-glycosides would act as neuraminidase inhibitors to prevent the release of new virions. As a preliminary study, a small library of 1,2,3-triazole-linked sialic acid derivatives has been synthesized in 71-89% yield. A disaccharide mimic of sialic acid has also been prepared using the α-sialic acid azide 1 and a C-8 propargyl sialic acid acceptor in 68% yield. A model sialic acid coated dendrimer was also synthesized from a per-propargylated pentaerythritol acceptor. These novel sialic acid derivatives were then evaluated as potential neuraminidase inhibitors using a 96-well plate fluorescence assay; micromolar IC50 values were observed, comparable to the known sialidase inhibitor Neu5Ac2en.
Collapse
Affiliation(s)
- Michel Weïwer
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, 110, 8th Street, Troy, NY 12180 (USA)
| | | | | | | |
Collapse
|
46
|
Honda T, Kubo S, Masuda T, Arai M, Kobayashi Y, Yamashita M. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. Bioorg Med Chem Lett 2009; 19:2938-40. [PMID: 19414262 DOI: 10.1016/j.bmcl.2009.04.067] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2009] [Revised: 04/14/2009] [Accepted: 04/16/2009] [Indexed: 10/20/2022]
Abstract
A series of ester prodrugs of 7-O-methyl derivative of Zanamivir (compound 3) was synthesized and their efficacy was evaluated in an influenza infected mice model by intranasal administration. Compound 7c (CS-8958), octanoyl ester prodrug of the C-9 alcohol of compound 3, was found to be much longer-acting than Zanamivir. Furthermore, the in vivo efficacies of compounds 12a, 12b, and 12c, the linear alkyl ester prodrug of the carboxylic acid, were comparable to that exerted by compound 7c.
Collapse
Affiliation(s)
- Takeshi Honda
- Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co, Ltd, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
47
|
Ritchie TJ, Luscombe CN, Macdonald SJF. Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet? J Chem Inf Model 2009; 49:1025-32. [DOI: 10.1021/ci800429e] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Timothy J. Ritchie
- Respiratory CEDD, GlaxoSmithKline Research Medicines Centre, Gunnels Wood Road, Stevenage SG1 2NY, U.K
| | - Christopher N. Luscombe
- Respiratory CEDD, GlaxoSmithKline Research Medicines Centre, Gunnels Wood Road, Stevenage SG1 2NY, U.K
| | - Simon J. F. Macdonald
- Respiratory CEDD, GlaxoSmithKline Research Medicines Centre, Gunnels Wood Road, Stevenage SG1 2NY, U.K
| |
Collapse
|
48
|
Cecioni S, Argintaru OA, Docsa T, Gergely P, Praly JP, Vidal S. Probing multivalency for the inhibition of an enzyme: glycogen phosphorylase as a case study. NEW J CHEM 2009. [DOI: 10.1039/b812540f] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
49
|
Abstract
Viruses, particularly those that are harmful to humans, are the 'silent terrorists' of the twenty-first century. Well over four million humans die per annum as a result of viral infections alone. The scourge of influenza virus has plagued mankind throughout the ages. The fact that new viral strains emerge on a regular basis, particularly out of Asia, establishes a continual socio-economic threat to mankind. The arrival of the highly pathogenic avian influenza H5N1 heightened the threat of a potential human pandemic to the point where many countries have put in place 'preparedness plans' to defend against such an outcome. The discovery of the first designer influenza virus sialidase inhibitor and anti-influenza drug Relenza, and subsequently Tamiflu, has now inspired a number of continuing efforts towards the discovery of next generation anti-influenza drugs. Such drugs may act as 'first-line-of-defence' against the spread of influenza infection and buy time for necessary vaccine development particularly in a human pandemic setting. Furthermore, the fact that influenza virus can develop resistance to therapeutics makes these continuing efforts extremely important. An overview of the role of the virus-associated glycoprotein sialidase (neuraminidase) and some of the most recent developments towards the discovery of anti-influenza drugs based on the inhibition of influenza virus sialidase is provided in this chapter.
Collapse
|
50
|
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2008; 53:186-92. [PMID: 18955520 DOI: 10.1128/aac.00333-08] [Citation(s) in RCA: 175] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this paper, the new potent NA inhibitor R-125489 is reported for the first time. R-125489 inhibited the NA activities of various type A and B influenza viruses, including subtypes N1 to N9 and oseltamivir-resistant viruses. The survival effect of R-125489 was shown to be similar to that of zanamivir when administered intranasally in a mouse influenza virus A/Puerto Rico/8/34 infection model. Moreover, we found that the esterified form of R-125489 showed improved efficacy compared to R-125489 and zanamivir, depending on the acyl chain length, and that 3-(O)-octanoyl R-125489 (CS-8958) was the best compound in terms of its life-prolonging effect (P < 0.0001, compared to zanamivir) in the same infection model. A prolonged survival effect was observed after a single administration of CS-8958, even if it was given 7 days before infection. It is suggested that intranasally administered CS-8958 works as a long-acting NA inhibitor and shows in vivo efficacy as a result of a single intranasal administration.
Collapse
|